|
A phase 2, multicenter, open-label study to evaluate the efficacy and safety of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC). |
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; Kolltan Pharmaceuticals; Merck; Merck Serono |
Research Funding - AVEO; Bristol-Myers Squibb; Genentech; Lilly; Merck; VentiRx |
|
|
Honoraria - Bristol-Myers Squibb; Lilly; Merck; Pfizer |
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Merck; Pfizer |
Research Funding - Bristol-Myers Squibb; Exelixis |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Pfizer |
|
|
Consulting or Advisory Role - Merck; Pfizer |
Research Funding - AstraZeneca (Inst); Biothera (Inst); Celgene (Inst); Celldex (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
|
Stock and Other Ownership Interests - Celldex |
|
|
No Relationships to Disclose |
|
|
|
|
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Cerulean Pharma; Heat Biologics; Kolltan Pharmaceuticals; Pfizer; Takeda; Zymeworks |
Research Funding - Celldex (Inst); Cleave Biosciences (Inst); Heat Biologics (Inst); Macrogenics (Inst); Merck (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Cerulean Pharma; Heat Biologics; Kolltan Pharmaceuticals; Pfizer; Takeda; Zymeworks |